Tamoxifen is safe and effective in gynecological cancer patients with renal dysfunction

International Journal of Gynecological Cancer

Volumn 18, Issue 4, 2008, Pages 648-651

  Sirisabya, N ^a,b   Li, Y ^a,c   Jaishuen, A ^a,d   Zheng, H G ^a   Gershenson, D M ^a   Kavanagh, J J ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^d MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Chronic kidney disease; Gynecological cancer; Renal dysfunction; Renal failure; Tamoxifen

Indexed keywords

TAMOXIFEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PATIENT; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CREATININE CLEARANCE; DEMOGRAPHY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEMALE GENITAL PRURITUS; GYNECOLOGIC CANCER; HOT FLUSH; HUMAN; KIDNEY DYSFUNCTION; MULTIPLE CYCLE TREATMENT; NAUSEA; OVARY CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT RESPONSE; UTERINE TUBE CARCINOMA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; TAMOXIFEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 47649086059     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.01069.x     Document Type: Article

References (27)

1. Tamoxifen (systemic). In : Board TME, ed. USP DI drug information for the health care professional. Greenwood Village, CO : Micromedex, 2005 : 310.
2. Clemons M, Danson S, Howell A. Tamoxifen ('Nolvadex'): a review. Cancer Treat Rev 2002 28 : 165 80.
3. Hatch KD, Beecham JB, Blessing JA et al. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 1991 68 : 269 71.
4. Zheng HG, Kavanagh JJ, Hu W et al. Hormonal therapy in ovarian cancer. Int J Gynecol Cancer 2007 17 : 325 38.
5. Van Der Velden J, Gitsch G, Wain GV et al. Tamoxifen in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 1995 5 : 301 5.
6. Williams CJ. Tamoxifen for relapse ovarian cancer. Cochrane Database Syst Rev 2001 1 : CD001034.
7. Perez-Garcia JL, Carrasco EM. Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systemic review of the literature and implications for future research. Gynecol Oncol 2002 84 : 201 9.
8. Markman M, Iseminger KA, Hatch KD et al. Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group ancillary report. Gynecol Oncol 1996 62 : 4 6.
9. Trope C, Marth C, Kaern J. Tamoxifen in the treatment of recurrent ovarian carcinoma. Eur J Cancer 2000 36 : 59 67.
10. Markman M, Webster K, Zanotti K et al. Use of tamoxifen in asymptomatic patients with recurrent small-volume ovarian cancer. Gynecol Oncol 2004 93 : 390 3.
11. Tamoxifen. CCO formulatory tamoxifen revised. Available at : http://www.cancercare.on.ca/pdfdrugs/tamoxife.pdf. Accessed February 15, 2007.
12. Sutherland CM, Sternson LA, Muchmore JH et al. Effect of impaired renal function on tamoxifen. J Surg Oncol 1984 27 : 222 3.
13. Fabian C, Sternson L, El-Serafi M et al. Clinical pharmacology of tamoxifen in patients with breast cancer. Cancer 1981 48 : 876 82.
14. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976 16 : 31 41.
15. Johnson D, Usherwood T. Automated reporting of GFR - coming soon to a laboratory near you!. Aust Fam Physician 2005 34 : 925 31.
16. Eknoyan G, Levin N : Clinical Practice Guidelines: Final Guideline Summaries from the Work Groups of the National Kidney Foundation - Dialysis Outcomes Quality Initiative. New York, NY : National Kidney Foundation, 1997.
17. The NCI common toxicity criteria version 2. 1999. Available at : http://ctep.info.nih.gov/reporting/ctc_archive.html. Accessed February 20, 2007.
18. Vergote I, Rustin GJ, Eisenhauer EA et al. Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst 2000 92 : 1534 5.
19. Rustin GJ, Timmers P, Nelstrop A et al. Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide. J Clin Oncol 2006 24 : 45 51.
20. Marth C, Sorheim N, Kaern J et al. Tamoxifen in the treatment of recurrent ovarian carcinoma. Int J Gynecol Cancer 1997 7 : 256 61.
21. Landoni F, Epis A, Gorga G et al. Hormonal treatment in advanced epithelial ovarian cancer. In Pannuti F, ed. Anti-oestrogens in oncology. Past, present and prospects: proceedings of the International Symposium of Hormonotherapy in Bolonga, 6-8 June, 1985. Excerpta Medica New York, NY : Elsevier Science Pub. Co., 1985 : 262 5.
22. Osborne RJ, Malik ST, Slevin ML et al. Tamoxifen in refractory ovarian cancer. The use of a loading dose schedule. Br J Cancer 1988 57 : 115 6.
23. Jager W, Sauerbrei W, Beck E et al. A randomized comparison of triptorelin and tamoxifen as treatment of progressive ovarian cancer. Anticancer Res 1995 15 : 2639 42.
24. Weiner SA, Alberts DS, Surwitt EA et al. Tamoxifen therapy in recurrent epithelial ovarian carcinoma. Gynecol Oncol 1987 27 : 208 13.
25. Ahlgren JD, Ellison NM, Gottlieb RJ et al. Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program. J Clin Oncol 1993 11 : 1957 68.
26. Shirey DR, Kavanagh JJ, Gershenson DM et al. Tamoxifen, therapy of epithelial ovarian cancer. Obstet Gynecol 1985 66 : 575 81.
27. Slevin ML, Harvey VJ, Osborne RJ et al. A phase II study of tamoxifen in ovarian cancer. Eur J Cancer Clin Oncol 1987 22 : 309 12.